MedTrace Logo

Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies

NCT05042908 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-05-21

No results posted yet for this study

Summary

This study is a single-arm, dose-escalation phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of LBL-003 injection in patients with advanced malignant tumors.

Conditions

  • Advanced Malignant Tumor

Interventions

DRUG

LBL-003 Injection

LBL-003 was given every two weeks for treatment

Sponsors & Collaborators

  • Henan Cancer Hospital

    collaborator OTHER_GOV

  • Hunan Cancer Hospital

    collaborator OTHER

  • Shandong Cancer Hospital and Institute

    collaborator OTHER

  • Nanjing Leads Biolabs Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Suxia Luo · Henan Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-02
Primary Completion
2023-04-10
Completion
2023-04-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05042908 on ClinicalTrials.gov